Reaction
Hormone-Refractory Prostate Cancer reporting signals
As of the last recalculation, Hormone-Refractory Prostate Cancer appears in 1,158 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN (PRR 234.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Lutetium Lu 177 Vipivotide Tetraxetan | 150 | 234.9 | 237.6 |
| Abiraterone | 112 | 163.6 | 164.9 |
| Bicalutamide | 101 | 130.4 | 131.3 |
| Abiraterone Acetate | 150 | 75.1 | 75.4 |
| Enzalutamide | 181 | 65.4 | 65.6 |
| Docetaxel Anhydrous | 186 | 58.9 | 59.1 |
| Docetaxel | 186 | 58.9 | 59.1 |
| Leuprolide Acetate | 171 | 46.3 | 46.4 |
| Olaparib | 29 | 25.5 | 25.6 |
| Apalutamide | 16 | 24.8 | 24.8 |
| Goserelin | 15 | 20.3 | 20.4 |
| Zoledronic Acid | 24 | 11.0 | 11.0 |
| Rucaparib | 4 | 8.2 | 8.2 |
| Relugolix | 8 | 6.1 | 6.1 |
| Denosumab | 65 | 6.1 | 6.1 |